Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03937791 · OUTCOME

Number of Grade 2 Adverse Events Unlikely Related to Drug in Participants Who Received E7 T-Cell Receptor (TCR) T Cells Administered in a Low Intensity Setting Without Conditioning or Systemic Aldesleukin

Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions · Source last updated 2021-04-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
adverse events
Interval / dispersion
Not reported
Time frame
30 days following the last dose of study therapy

What was measured

Grade 2 adverse event is moderate.

Groups in this outcome

Arm 1/1x10^11 E7 T Cell Receptor (TCR) T Cells

1x10\^11 E7 TCR T cells will be administered intravenously over 20 to 30 minutes on day 0. E7 T Cell Receptor (TCR): One dose of E7 TCR T cells (1x10\^11 cells) will be administered intravenously over 20 to 30 minutes.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm 1/1x10^11 E7 T Cell Receptor (TCR) T Cells1

Reported measurements

Source class 1
Values in adverse events · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm 1/1x10^11 E7 T Cell Receptor (TCR) T Cells1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
denoms
  1. counts
    1. group Id
      OG000
      value
      1
    units
    Participants
description
Grade 2 adverse event is moderate.
groups
  1. description
    1x10\^11 E7 TCR T cells will be administered intravenously over 20 to 30 minutes on day 0. E7 T Cell Receptor (TCR): One dose of E7 TCR T cells (1x10\^11 cells) will be administered intravenously over 20 to 30 minutes.
    id
    OG000
    title
    Arm 1/1x10^11 E7 T Cell Receptor (TCR) T Cells
param Type
NUMBER
reporting Status
POSTED
time Frame
30 days following the last dose of study therapy
title
Number of Grade 2 Adverse Events Unlikely Related to Drug in Participants Who Received E7 T-Cell Receptor (TCR) T Cells Administered in a Low Intensity Setting Without Conditioning or Systemic Aldesleukin
type
SECONDARY
unit Of Measure
adverse events

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice